Herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) are highly prevalent within the human population and are characterized by lifelong infections and sporadic recurrences due to latent neuron infection. Upon reactivations, HSVs may manifest either, symptomatically or asymptomatically and be shed onto others through mucosae body fluids. Although, HSVs can produce severe disease in humans, such as lifethreatening encephalitis and blindness, the most common symptoms are skin and mucosal lesions in the oro-facial and the genital areas. Nucleoside analogs with antiviral activity can prevent severe HSV infection, yet they are not very effective for treating skin manifestations produced by these viruses, as they only reduce in a few days at most the duration of lesions. Additionally, HSV variants that are resistant to these antivirals may arise, especially in immunosuppressed individuals. Thus, new antivirals that can reduce the severity and duration of these cutaneous manifestations would certainly be welcome. Here, we review currently available anti-herpetic therapies, novel molecules being assessed in clinical trials and new botanical compounds reported in the last 20 years with antiviral activities against HSVs that might represent future treatments against these viruses.

No abstract

No abstract

No abstract

No abstract

The shear-sensitive microalga Heterosigma akashiwo is known to produce brevetoxin-like compounds that are active in voltage-dependent sodium channels. In this work, we present a study on the production of anaesthetic extracts from H. akashiwo biomass obtained in low-shear bioreactors at different growth phases. The photobioreactors (PBRs) used had specific configurations and were operated in such a way as to avoid cellular damage by hydrodynamic stress. Cultures were developed in small static-control flasks and PBRs with volumes ranging from 1.5 L to 200 L. The bioactivity of the produced extracts was assessed in vitro (Neuro-2a cell-based assay) and in vivo (Zebra fish model). Bioactivity depended slightly on the growth phase and culture system, with greater toxicity with the Neuro-2a model when stationary-phase extracts were used. Interestingly, extracts were not cytotoxic against other human cell lines. Steady production of anaesthetic bioactives was observed. In vivo anaesthetic efficacy, assessed with the Zebra fish model, was similar to that of commercial products, and without any observed mortality at 24-h post exposure.

No abstract

No abstract